Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) Shares Outstanding (Weighted Average) (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $5.13 as the latest value for Q3 2024.

  • Quarterly Shares Outstanding (Weighted Average) fell 100.0% to $5.13 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $5.13 through Sep 2024, down 100.0% year-over-year, with the annual reading at $50000.0 for FY2023, 96.04% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $5.13 in Q3 2024 for Pasithea Therapeutics, down from $1.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $24.4 million in Q3 2022 to a low of $5.13 in Q3 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $5.6 million across 4 years, with a median of $1.3 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 357.37% in 2022 and later crashed 100.0% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $276000.0 in 2021, then surged by 357.37% to $1.3 million in 2022, then plummeted by 96.04% to $50000.0 in 2023, then plummeted by 99.99% to $5.13 in 2024.
  • Business Quant data shows Shares Outstanding (Weighted Average) for KTTA at $5.13 in Q3 2024, $1.0 million in Q2 2024, and $1.0 million in Q1 2024.